Overview: CD5 Immunohistochemistry TestIntroduction: The CD5 Immunohistochemistry Test detects CD5 protein to diagnose T-cell or B-cell lymphomas, causing lymph node swelling. Aligned with 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected lymphomas, particularly CLL/SLL or mantle cell lymphoma.
Other Names: CD5 IHC Assay, Lymphoma CD5 Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: CD5 testing began in the 1980s with lymphoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects CD5 to diagnose T-cell or B-cell lymphomas, guides treatment, and evaluates patients with lymph node swelling.
Test Parameters: 1. CD5 Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lymph node swelling, fatigue, or lymphoma symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, fatigue, night sweats, or family history of lymphomas. Include current medications, especially chemotherapy.
Consent: Written consent required, detailing the tests purpose, lymphoma implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect CD5 in lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for CLL/SLL or mantle cell lymphoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive CD5 staining suggests CLL/SLL or mantle cell lymphoma, guiding chemotherapy or immunotherapy. Negative staining may require further lymphoma marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD23 IHC, cyclin D1 IHC, or flow cytometry to confirm lymphoma diagnosis.
Test Limitations: Not specific to one lymphoma type; other conditions may express CD5. Clinical correlation is needed.
References: WHO Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
